| 郭克锋,常英英,李宗民,柳玉花,员东星.HPV-DNA、p16和EGFR在口咽癌诊断中的临床价值分析[J].,2023,(3):560-564 |
| HPV-DNA、p16和EGFR在口咽癌诊断中的临床价值分析 |
| Clinical Value of HPV-DNA, p16 and EGFR in Diagnosis of Oropharyngeal Carcinoma |
| 投稿时间：2022-04-23 修订日期：2022-05-19 |
| DOI：10.13241/j.cnki.pmb.2023.03.032 |
| 中文关键词: 口咽癌 人乳头瘤病毒 表皮生长因子受体 p16 |
| 英文关键词: Oropharyngeal carcinoma Human papillomavirus Epidermal growth factor receptor p16 |
| 基金项目:河南省科技发展计划（河南省科技厅 豫科（2022）13号） |
|
| 摘要点击次数: 626 |
| 全文下载次数: 384 |
| 中文摘要: |
| 摘要 目的：探讨人乳头状瘤病毒感染状态（HPV-DNA）、p16基因和表皮生长因子受体（EGFR）在口咽癌诊断中的临床价值。方法：选取我院2015年5月到2021年10月共收治的口咽癌60患者作为研究对象，进行回顾性分析，分析HPV-DNA、p16和EGFR在口咽癌患者的表达情况，分析HPV-DNA、p16和EGFR与肿瘤病理的关系，之后对所有患者进行随访，应用Cox比例风险回归模型分析患者的生存情况与HPV-DNA、p16和EGFR的关系。结果：HPV-DNA、p16和EGFR在口咽癌患者中的阳性表达对比无明显差异（P＜0.05）；HPV-DNA阳性患者与阴性患者性别、年龄对比无明显差异（P＞0.05），肿瘤分期与淋巴结受累情况对比差异显著（P＜0.05）；p16阳性患者与阴性患者性别、年龄、肿瘤分期对比无差异（P＞0.05），淋巴结受累情况对比差异显著（P＜0.05）；EGFR阳性患者与阴性患者性别、年龄对比无明显差异（P＞0.05），肿瘤分期与淋巴结受累情况对比差异显著（P＜0.05）；在患者生存分析之中，有20例患者因为随访数据不全被剔除，其中无病生存率之中，P16/EGFR、p16对比差异显著（P＜0.05），总生存率中淋巴结转移、P16/EGFR对比差异显著（P＜0.05）；口咽癌中HPV-DNA水平与p16水平呈现负相关关系，与EGFR呈现正相关关系，p16与EGFR呈现负相关关系（P＜0.05）。结论：p16的表达是口咽癌最可靠的预后标志物，而且可能是HPV阳性口咽癌的替代标记物。HPV1/p161肿瘤倾向于减少EGFR的表达，但使用两种免疫组织学标记物对预后有显著影响。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical value of HPV-DNA, p16 gene and EGFR in the diagnosis of oropharyngeal carcinoma. Methods: 60 Patients with oropharyngeal cancer admitted to our hospital from May 2015 to October 2021 were selected as the research imagination. The expression of HPV-DNA, p16 and EGFR in oropharyngeal cancer patients was analyzed retrospectively. The relationship between HPV-DNA, p16 and EGFR and tumor pathology was analyzed. All patients were followed up. Cox proportional hazard regression model was used to analyze the survival of patients and HPV-DNA, p16 and E GFR relationship. Results: There was no difference in the positive expression of HPV-DNA, p16 and EGFR in oropharyngeal cancer patients(P<0.05); there was no difference in gender and age between HPV-DNA positive patients and negative patients(P>0.05), tumor stage and lymph node involvement were not different (P>0.05) There was no significant difference in gender, age and tumor stage between p16 positive patients and negative patients (P>0.05), but lymph node involvement was different(P<0.05); there was no difference in gender and age between EGFR positive and negative patients(P>0.05), but there was difference between tumor stage and lymph node involvement(P<0.05); In the survival analysis of patients, 20 patients were excluded because of incomplete follow-up data. Among the disease-free survival rate, the difference between p16 / EGFR and p16 was significant(P<0.05), and the difference of lymph node metastasis and p16 / EGFR in overall survival rate was significant(P<0.05). The level of HPV-DNA in oropharyngeal carcinoma was negatively correlated with p16 level, positively correlated with EGFR, and negatively correlated with p16 and EGFR(P<0.05). Conclusion: The expression of p16 is the most reliable prognostic marker of oropharyngeal carcinoma, and may be an alternative marker of HPV positive oropharyngeal carcinoma. HPV1 / p161 tumors tend to reduce the expression of EGFR, but the use of two immunohistochemical markers has a significant impact on the prognosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
